Corvus Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (CRVS) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2016 to Q4 2025

Type / Class
Equity / Common Stock, $0.0001 par value per share
Symbol
CRVS on Nasdaq
Shares outstanding
78,024,641
Price per share
$6.68
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
26,771,704
Total reported value
$206,134,192
% of total 13F portfolios
0%
Share change
+7,118,891
Value change
+$54,826,976
Number of holders
81
Price from insider filings
$6.68
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Corvus Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (CRVS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ORBIMED ADVISORS LLC 10% -16% $66,290,001 -$9,057,756 8,609,091 -12% ORBIMED ADVISORS LLC 23 Jan 2026
MILLER RICHARD A MD 7.8% +1.2% $40,653,959 +$5,781,901 6,085,922 +17% Richard A. Miller 31 Dec 2025
BlackRock, Inc. 5.4% $29,594,309 4,015,510 BlackRock, Inc. 30 Sep 2025
VANGUARD GROUP INC 5.2% $29,825,811 3,873,482 The Vanguard Group 31 Dec 2025
ADAMS STREET PARTNERS LLC 3.9% $25,222,243 3,275,616 Adams Street Partners, LLC 23 Jan 2026

As of 31 Dec 2025, 81 institutional investors reported holding 26,771,704 shares of Corvus Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (CRVS). This represents 34% of the company’s total 78,024,641 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Corvus Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (CRVS) together control 33% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 6.5% 5,056,361 +7.3% 0% $38,933,979
VANGUARD GROUP INC 5% 3,873,482 +12% 0% $29,825,811
MORGAN STANLEY 4.6% 3,567,908 +478% 0% $27,472,892
ADAMS STREET PARTNERS LLC 4.2% 3,275,616 0% 9.6% $25,222,243
STATE STREET CORP 3.6% 2,788,223 +177% 0% $21,469,317
Vivo Capital, LLC 2.9% 2,234,566 0% 1.1% $17,206,158
GEODE CAPITAL MANAGEMENT, LLC 1.9% 1,473,026 +1.1% 0% $11,345,051
DCF Advisers, LLC 0.93% 729,000 1.9% $5,613,300
GOLDMAN SACHS GROUP INC 0.71% 553,327 +24% 0% $4,260,618
BARCLAYS PLC 0.51% 394,766 +28% 0% $3,039,698
JANE STREET GROUP, LLC 0.48% 378,297 +456% 0% $2,912,886
MARSHALL WACE, LLP 0.28% 216,248 0% $1,665,111
UBS Group AG 0.27% 212,006 +31% 0% $1,632,446
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.22% 171,173 -3.7% 0% $1,318,032
Empirical Financial Services, LLC d.b.a. Empirical Wealth Management 0.21% 167,400 -1.1% 0.02% $1,288,980
TOWERVIEW LLC 0.18% 140,000 -18% 0.78% $1,078,000
Bank of New York Mellon Corp 0.17% 131,628 +4% 0% $1,013,537
Squarepoint Ops LLC 0.13% 104,820 0% $807,114
Rafferty Asset Management, LLC 0.13% 99,724 0% $767,875
TEMA ETFS LLC 0.1% 79,698 +35% 0.05% $613,675
RHUMBLINE ADVISERS 0.09% 70,727 -14% 0% $544,591
Nuveen, LLC 0.09% 68,064 0% 0% $524,093
JACKSON SQUARE CAPITAL, LLC 0.08% 63,773 0% 0.1% $491,052
WELLS FARGO & COMPANY/MN 0.08% 62,623 +72% 0% $482,198
ALPS ADVISORS INC 0.08% 61,318 0% $472,149

Institutional Holders of Corvus Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (CRVS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 26,771,704 $206,134,192 +$54,826,976 $7.70 81
2025 Q3 41,673,686 $307,002,895 +$4,353,875 $7.37 101
2025 Q2 41,781,497 $167,123,225 +$27,653,733 $4.00 92
2025 Q1 36,268,523 $115,333,082 -$7,370,970 $3.18 87
2024 Q4 37,723,156 $201,818,514 +$34,704,752 $5.35 85
2024 Q3 30,026,264 $158,538,176 +$12,733,385 $5.28 61
2024 Q2 27,591,708 $50,216,835 +$17,655,345 $1.82 46
2024 Q1 17,899,766 $31,860,771 -$2,279,392 $1.78 46
2023 Q4 19,183,314 $33,762,501 +$90,871 $1.76 46
2023 Q3 19,186,334 $28,011,450 -$1,230,958 $1.46 52
2023 Q2 19,491,995 $44,633,999 +$707,708 $2.29 51
2023 Q1 20,767,710 $18,897,208 -$183,902 $0.91 35
2022 Q4 21,363,573 $18,157,963 -$606,364 $0.85 38
2022 Q3 22,082,952 $18,073,081 -$3,458,421 $0.82 38
2022 Q2 25,594,950 $25,339,212 -$3,279,778 $0.99 39
2022 Q1 27,387,121 $44,913,000 -$1,201,434 $1.64 52
2021 Q4 27,678,421 $66,701,000 -$7,831,144 $2.41 58
2021 Q3 28,180,241 $136,388,000 +$22,907,893 $4.84 55
2021 Q2 23,673,230 $63,207,000 +$8,569,595 $2.67 44
2021 Q1 20,393,400 $62,807,000 +$12,093,812 $3.08 45
2020 Q4 16,311,910 $58,071,014 -$3,250,489 $3.56 34
2020 Q3 17,216,699 $69,036,016 -$11,684,715 $4.01 33
2020 Q2 20,440,680 $55,598,011 -$392,205 $2.72 34
2020 Q1 20,651,240 $43,573,167 -$3,308,904 $2.11 36
2019 Q4 20,779,789 $113,038,430 -$10,373,847 $5.44 35
2019 Q3 22,891,685 $68,903,436 -$4,060,912 $3.01 34
2019 Q2 24,342,578 $90,952,754 -$1,503,000 $3.74 43
2019 Q1 24,763,106 $99,529,635 -$1,002,484 $4.02 56
2018 Q4 25,129,757 $92,163,767 -$1,838,747 $3.67 60
2018 Q3 25,496,765 $218,762,586 -$3,322,901 $8.58 60
2018 Q2 25,906,899 $284,454,314 +$6,770,964 $10.98 56
2018 Q1 25,285,587 $287,758,705 +$90,614,709 $11.53 54
2017 Q4 17,418,578 $180,457,571 -$3,160,000 $10.36 53
2017 Q3 17,544,055 $279,715,086 +$1,015,923 $15.94 52
2017 Q2 17,504,516 $211,804,598 -$2,803,453 $12.10 48
2017 Q1 17,335,240 $360,050,125 +$9,744,515 $20.77 52
2016 Q4 17,484,501 $250,048,615 +$17,391,608 $14.30 53
2016 Q3 16,266,787 $267,555,203 -$17,049,726 $16.45 44
2016 Q2 14,645,573 $208,464,147 +$13,774,406 $14.26 43
2016 Q1 13,758,120 $199,086,000 +$197,418,000 $14.50 31